Gemini Therapeutics Competitors

Gemini Therapeutics (NASDAQ:GMTX) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and ImmunityBio, as reported by MarketBeat.com.

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 43.84%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than ImmunityBio.

Earnings and Valuation

This table compares Gemini Therapeutics and ImmunityBio's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Gemini Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Summary

Gemini Therapeutics beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and Immunocore, as reported by MarketBeat.com.

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 42.05%. Given Gemini Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Immunocore.

Earnings and Valuation

This table compares Gemini Therapeutics and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Gemini Therapeutics and Immunocore's net margins, return on equity and return on assets.

Summary

Gemini Therapeutics beats Immunocore on 3 of the 3 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and BioAtla, as reported by MarketBeat.com.

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. BioAtla has a consensus target price of $58.00, indicating a potential upside of 21.49%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than BioAtla.

Earnings and Valuation

This table compares Gemini Therapeutics and BioAtla's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Gemini Therapeutics and BioAtla's net margins, return on equity and return on assets.

Summary

Gemini Therapeutics beats BioAtla on 1 of the 1 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and Cullinan Oncology, as reported by MarketBeat.com.

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Cullinan Oncology has a consensus target price of $48.25, indicating a potential upside of 37.07%. Given Gemini Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Cullinan Oncology.

Earnings and Valuation

This table compares Gemini Therapeutics and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Gemini Therapeutics and Cullinan Oncology's net margins, return on equity and return on assets.

Summary

Gemini Therapeutics beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Earnings and Valuation

This table compares Gemini Therapeutics and Silverback Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and Silverback Therapeutics, as reported by MarketBeat.com.

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Silverback Therapeutics has a consensus target price of $50.25, indicating a potential upside of 33.50%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Silverback Therapeutics.

Profitability

This table compares Gemini Therapeutics and Silverback Therapeutics' net margins, return on equity and return on assets.

Summary

Gemini Therapeutics beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Gemini Therapeutics and Kinnate Biopharma's revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent recommendations for Gemini Therapeutics and Kinnate Biopharma, as reported by MarketBeat.

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Kinnate Biopharma has a consensus target price of $52.00, indicating a potential upside of 75.44%. Given Gemini Therapeutics' higher possible upside, equities research analysts clearly believe Gemini Therapeutics is more favorable than Kinnate Biopharma.

Profitability

This table compares Gemini Therapeutics and Kinnate Biopharma's net margins, return on equity and return on assets.

Summary

Gemini Therapeutics beats Kinnate Biopharma on 1 of the 1 factors compared between the two stocks.